0.9329
price down icon4.65%   -0.0455
after-market 시간 외 거래: .93 -0.0029 -0.31%
loading

Hoth Therapeutics Inc 주식(HOTH)의 최신 뉴스

pulisher
Apr 02, 2025

Hoth Therapeutics reports Alzheimer’s drug candidate success By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Flat on Hookup with Washington Univ. - Baystreet.ca

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics reports Alzheimer’s drug candidate success - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Breakthrough: New Alzheimer's Drug Cuts Key Brain Marker by 15%University Study Reveals - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours - PR Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Hoth Therapeutics receives USPTO filing receipt for HT-001 patent application - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage - PR Newswire

Mar 31, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics Inc. (HOTH) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Major Progress: Hoth's Cancer-Fighting Drug Secures Patent Protection and Launches Critical Safety Study - Stock Titan

Mar 26, 2025
pulisher
Mar 24, 2025

Hoth Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Mar 24, 2025
pulisher
Mar 20, 2025

Hoth Therapeutics (HOTH) Projected to Post Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Balance Sheet Breakdown: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Mar 19, 2025
pulisher
Mar 19, 2025

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Hoth reports progress in GIST treatment with HT-KIT By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Hoth reports progress in GIST treatment with HT-KIT - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment - PR Newswire

Mar 18, 2025
pulisher
Mar 18, 2025

Revolutionary 24-Hour Cancer Treatment Success: Hoth's HT-KIT Destroys GIST Tumors in Breakthrough Study - Stock Titan

Mar 18, 2025
pulisher
Mar 17, 2025

Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Decreases By 24.8% - Defense World

Mar 17, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Dips on Drug Application - Baystreet.ca

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit Expanded Access application for HT-001 - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need - PR Newswire

Mar 10, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting - PR Newswire

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Hoth Therapeutics Announces Positive Findings On GDNF's Potential As A Game-Changer In Obesity Treatment And Reduced Fatty Liver Disease - MarketScreener

Mar 04, 2025
pulisher
Mar 04, 2025

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease - PR Newswire

Mar 04, 2025
pulisher
Mar 04, 2025

GDNF shows promise in obesity treatment, Hoth research finds - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Financial Contrast: Emmaus Life Sciences (OTCMKTS:EMMA) and Hoth Therapeutics (NASDAQ:HOTH) - Defense World

Mar 04, 2025
pulisher
Feb 17, 2025

HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN

Feb 17, 2025
pulisher
Feb 12, 2025

Hoth Therapeutics (NASDAQ:HOTH) Given Buy Rating at D. Boral Capital - Defense World

Feb 12, 2025
pulisher
Feb 10, 2025

Hoth Therapeutics to Present at the LD Micro Main Event (XII) - ACCESS Newswire

Feb 10, 2025
pulisher
Feb 10, 2025

What to expect from HOTH’s earnings report this quarter? - US Post News

Feb 10, 2025
pulisher
Feb 10, 2025

Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic - Contract Pharma

Feb 10, 2025
pulisher
Feb 10, 2025

HOTH's Cancer Breakthrough: Strategic Alliance Accelerates Novel HT-KIT Therapeutic Research - StockTitan

Feb 10, 2025
pulisher
Feb 08, 2025

Hoth Therapeutics expands at-the-market offering by $5 million - Investing.com Australia

Feb 08, 2025
pulisher
Jan 27, 2025

Research Analysts Set Expectations for HOTH FY2024 Earnings - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at HC Wainwright - Defense World

Jan 26, 2025
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
자본화:     |  볼륨(24시간):